Clinical Trials

376 enrolled

BreastCNSGastrointestinalGynecologicHead & NeckThoracic

Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT05941507 2025-09-24

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Phase 1/2 Recruiting

300 enrolled

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Glioblastoma, Head and Neck Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT07007182 2025-09-05

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

Phase 2 Not yet recruiting

54 enrolled

Stomach Neoplasms

NCT05576480 2025-08-28

SPARC

55 enrolled

Rectal Neoplasms

NCT04191421 2025-08-22

Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

Phase 1/2 Completed

35 enrolled 10 charts

Phase 1 Active not recruiting

Pancreatic Neoplasms

NCT05607953 2025-07-04

Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

60 enrolled

Locally Advanced Pancreatic Adenocarcinoma

NCT06507371 2025-06-26

mRCAT-III

Phase 3 Recruiting

170 enrolled

Rectal Neoplasms

NCT06728657 2025-06-18

TORCH-G

Phase 2 Suspended

68 enrolled

Stomach Adenocarcinoma

NCT01351103 2025-06-13

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

BreastDermatologicGastrointestinal

185 enrolled

Esophageal Squamous Cell Carcinoma, Melanoma, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT04821765 2025-05-30

Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer

Phase 2 Completed

35 enrolled

Esophageal Neoplasms

NCT06280495 2025-05-30

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

Phase 2/3 Recruiting

156 enrolled

GastrointestinalGenitourinaryGynecologicHead & Neck

Colorectal Neoplasms

NCT04152018 2025-05-28

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Phase 1 Terminated

85 enrolled

Squamous Cell Carcinoma of Head and Neck, Bile Duct Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT06908031 2025-05-14

CRIT

49 enrolled

Rectal Neoplasms

NCT06794086 2025-05-13

SPARKLE-L

Phase 3 Recruiting

24 enrolled

Colorectal Neoplasms

NCT04581343 2025-05-04

PanCAN-SR1

10 enrolled 26 charts

Metastatic Pancreatic Ductal Adenocarcinoma

NCT06928584 2025-04-15

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

221 enrolled

Locally Recurrent Rectal Cancer

NCT04866836 2025-03-21

A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors

Phase 2 Terminated

20 enrolled

BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

Cholangiocarcinoma

NCT03058289 2025-02-27

IT-01

Phase 1/2 Completed

111 enrolled 21 charts

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT06840665 2025-02-21

MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer

46 enrolled

Phase 1 Active not recruiting

Locally Advanced Rectal Cancer

NCT03860272 2025-02-06

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

499 enrolled

GastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT06792162 2025-01-24

PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer

20 enrolled

Stomach Neoplasms

NCT04518280 2025-01-17

TORCH

Phase 2 Completed

130 enrolled

Locally Advanced Rectal Cancer

NCT04171141 2025-01-16

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

Phase 1 Terminated

79 enrolled 42 charts

Digestive System Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT05555888 2025-01-15

TORCH-E

34 enrolled

Early Low Rectal Cancer

NCT05972655 2025-01-09

mRCAT

32 enrolled

Low Rectal Cancer

NCT04672434 2024-12-09

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

GastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

48 enrolled

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Esophageal Neoplasms, Mesothelioma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06665087 2024-10-30

CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC

Phase 2 Not yet recruiting

110 enrolled

Colonic Neoplasms, Rectal Neoplasms

NCT02325739 2024-10-21

FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression

Phase 1/2 Completed

172 enrolled 33 charts

BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Hepatocellular

NCT03207867 2024-10-09

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Phase 2 Terminated

315 enrolled 73 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Pancreatic Neoplasms, Spinocerebellar Degenerations, Triple Negative Breast Neoplasms

NCT05628038 2024-10-01

TORCH-R

93 enrolled

Rectal Neoplasms

NCT03716596 2024-09-20

CISPD-2

Phase 1 Terminated

8 enrolled

Pancreatic Neoplasms

NCT06349044 2024-08-27

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

Phase NA Recruiting

120 enrolled

Carcinoma, Hepatocellular

NCT04641871 2024-06-26

Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

78 enrolled

Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis, Cholangiocarcinoma

NCT03291054 2024-06-11

Epacadostat and Pembrolizumab in Patients With GIST

Phase 2 Terminated

1 enrolled 1 chart

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT06396637 2024-05-02

PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC

20 enrolled

Phase 2 Active not recruiting

Pancreatic Adenocarcinoma Metastatic

NCT04301557 2024-04-23

PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer

25 enrolled

GastrointestinalOther solid neoplasm

DMMR Colorectal Cancer

NCT06364787 2024-04-15

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma

Phase 1 Not yet recruiting

18 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Carcinoma, Hepatocellular

NCT06364800 2024-04-15

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody

18 enrolled

Carcinoma, Hepatocellular

NCT06122493 2023-11-08

Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma

48 enrolled

Esophageal Squamous Cell Carcinoma

NCT06120127 2023-11-07

IMPROVE

Phase 2 Unknown

80 enrolled

Colorectal Neoplasms

NCT03260712 2023-11-03

Pembrolizumab in Biliary Tract Cancer

Phase 2 Completed

50 enrolled